Envoy Medical Advances Fully Implanted Hearing Device Toward FDA Approval

Envoy Medical (NASDAQ: COCH) is advancing development of its Acclaim fully implanted cochlear implant, a first-of-its-kind hearing device designed to provide 24-hour hearing without external hardware. The company has completed enrollment in its pivotal clinical trial and is now collecting data ahead of a planned FDA submission. Unlike traditional cochlear implants, the Acclaim system is implanted entirely beneath the skin and uses the ear’s natural anatomy to capture sound.

Management believes the technology could significantly expand adoption among patients who have severe hearing loss but are reluctant to use traditional external cochlear implant systems. Envoy says the U.S. market alone includes millions of potential candidates, and recent clinical data has been encouraging as the company moves toward future regulatory milestones.

#EnvoyMedical
#COCH
#HearingLoss
#CochlearImplant
#MedicalDevices
#HealthTech
#HealthcareInnovation
#Biotech
#FDA
#ClinicalTrials
#MedicalTechnology
#Audiology
#HearingHealth
#JaneKing
#NewsOut